Effective Maintenance Treatment of Reflux Esophagitis with Low-Dose Lansoprazole

A Randomized, Double-Blind, Placebo-Controlled Trial

15 May 1996 | Volume 124 Issue 10 | Pages 859-867

Objective: To compare the efficacy of two doses of lansoprazole with that of placebo in preventing recurrence of erosive esophagitis in a 12-month period.

Design: Randomized, double-blind, parallel, placebo-controlled trial.

Setting: 25 U.S. medical centers.

Patients: 173 patients with documented healing of erosive esophagitis after 8 weeks of acid-suppressing therapy.

Intervention: Lansoprazole, 15 mg or 30 mg, or placebo once daily for as long as 12 months.

Measurements: Endoscopy and symptom evaluation after 1,2,3,6,9, and 12 months of treatment. Endoscopy was also done whenever symptoms suggested erosive changes.

Results: Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms. By month 1, 45% of placebo recipients remained healed compared with more than 90% of patients in either lansoprazole group. By month 12, only 24% of placebo recipients remained healed compared with 79% of patients receiving 15 mg of lansoprazole and 90% of patients receiving 30 mg of lansoprazole. During the same period, 35% of placebo recipients remained asymptomatic compared with 72% of recipients of 15 mg of lansoprazole and 67% of recipients of 30 mg of lansoprazole. The 15-mg and 30-mg lansoprazole doses did not differ significantly in maintaining healing and controlling symptoms. Follow-up after recurrence of erosion indicated that during the 12 months, 35% of placebo recipients and 2% of lansoprazole recipients had three or more recurrences.

Conclusion: Lansoprazole effectively maintains healing of erosive esophagitis. The 15-mg and 30-mg lansoprazole doses did not differ significantly for use as maintenance treatment.

Author and Article Information

From University of Oklahoma College of Medicine, Oklahoma City, Oklahoma; Baylor College of Medicine, Houston, Texas; and Medical College of Pennsylvania and Hahnemann University, Philadelphia, Pennsylvania.
Grant Support: By a grant from TAP Holdings, Inc., Deerfield, Illinois.
Requests for Reprints: Malcolm Robinson, MD, Oklahoma Foundation for Digestive Research, University of Oklahoma College of Medicine, 711 Stanton L. Young Boulevard, Suite 501, Oklahoma City, OK 73104.
Current Author Addresses: Dr. Robinson: Oklahoma Foundation for Digestive Research, University of Oklahoma College of Medicine, 711 Stanton L. Young Boulevard, Suite 501, Oklahoma City, OK 73104.